Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 31 of the 76 sources its claims cite were checked for support.
Abstract
Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune dysregulation, present before CAR T-cell therapy, was associated with treatment failure. Tumor expression of interferon (IFN) signaling, high blood levels of monocytic myeloid-derived suppressor cells (M-MDSCs), and high blood interleukin-6 and ferritin levels were each associated with a lack of durable response. Similar to other cancers, we found that in LBCL tumors, IFN signaling is associated with the expression of multiple checkpoint ligands, including programmed cell death–ligand 1, and these were higher in patients who lacked durable responses to CAR-T therapy. Moreover, tumor IFN signaling and blood M-MDSCs associated with decreased axi-cel expansion. Finally, patients with high tumor burden had higher immune dysregulation with increased serum inflammatory markers and tumor IFN signaling. These data support that immune dysregulation in LBCL promotes axi-cel resistance via multiple mechanistic programs: insufficient axi-cel expansion associated with both circulating M-MDSC and tumor IFN signaling, which also gives rise to expression of immune checkpoint ligands.
Overview
CoChat Summary
TL;DR
In patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel), pretherapy immune dysregulation—tumor interferon signaling, circulating monocytic myeloid-derived suppressor cells (M-MDSCs), and elevated inflammatory markers—was associated with lack of durable response. Tumor interferon signaling and M-MDSCs also associated with decreased axi-cel expansion, and high tumor burden was linked to greater systemic and tumor inflammation.
Key findings
- Among 105 axi-cel-treated patients, lack of durable response was associated with tumor interferon signaling, high blood M-MDSCs, and high blood interleukin-6 and ferritin levels.
- Pretreatment tumor biopsies showed higher malignant B-cell PD-L1 and MHC II in nondurable responders; RNA data showed enrichment of the tumor ISG.RS interferon signature in nondurable responders and the T-cell IFNG.GS signature in durable responders. Macrophage-associated genes CD163 (3.4-fold; P = .02) and Siglec-1 (2.9-fold; P < .001) were higher at baseline in nondurable responders.
- Median peak axi-cel levels were 10-fold higher in durable responders than nondurable responders (P = .01); patients with high baseline M-MDSCs (greater than median; 250 cells per μL) had 4-fold lower peak axi-cel expansion (P = .02), and tumor interferon signaling genes were highly expressed in patients with poor axi-cel expansion.
- High tumor burden (>150 mL metabolic tumor volume) was associated with higher ferritin, IL-6, IL-15, TNF-α, and ANG2/ANG1; in public NCICCR LBCL data, high ISG.RS was associated with multiple T-cell inhibitory ligands and with SOCS1 and KLHL6 mutations.
Methods
- Observational study of samples from 105 patients treated with axi-cel: 85 received standard-of-care therapy, 14 as part of a clinical trial, and 6 under the ZUMA-9 expanded access trial. Durable responders remained in remission with a minimum follow-up of 6 months after infusion; nondurable responders died of any cause or relapsed.
- Assays included multiplex immunofluorescence for CD19, CD20, CD3, PD-L1, MHC I, and MHC II (n = 26); NanoString IO360 gene expression (n = 35); RNA-sequencing (n = 18); flow cytometry for M-MDSCs; quantitative polymerase chain reaction for axi-cel expansion; and serum cytokine, ferritin, and CRP measurements.
- Analyses compared durable vs nondurable responders, used gene set enrichment and GSVA for interferon signatures, assessed correlations, and interrogated the public NCICCR-DLBCL data set for ISG.RS-associated features.
Limitations
- Paper-stated: the study was observational and therefore limited to describing associations rather than concluding causal links.
- Paper-stated: multivariable modeling of clinical outcomes using tumor genetics, peripheral blood cytokines, metabolic tumor volume, tumor microenvironment characteristics, and circulating immune subsets would be ideal, but the authors could not analyze every biomarker in each patient because of sample-collection constraints.
- Evident from the text: several assay-specific sample sizes were small (e.g., multiplex immunofluorescence n = 26, NanoString n = 35, RNA-sequencing n = 18, M-MDSC/TME overlap n = 11), and patients were treated across standard-of-care, clinical trial, and expanded-access settings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
15 Valid · 1 Not valid · 18 Not checked · 105 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“patients with lymphoma have high levels of circulating myeloid-derived suppressor cells (MDSCs) compared with healthy control subjects”
What the sources say
- Disputedcites [16] Lin, 2011, Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma, Blood sourceExperimental — accuracy not yet measured
The Results distinguish MDSCs from the CD14+HLA-DRlow/− suppressive monocytes studied in lymphoma patients. They report that circulating MDSCs were infrequent and not significantly higher than in healthy controls, contrary to the claim. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [20] Azzaoui, 2016, T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells, Blood sourceExperimental — accuracy not yet measured
The section “MDSCs are expanded in peripheral blood of DLBCL patients” reports significantly higher circulating MDSC counts in patients with diffuse large B-cell lymphoma than in healthy donors. The claim says “patients with lymphoma” generally, while this study’s comparison is limited to that lymphoma subtype; the indexed passage provides no page number. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients with active disease experience systemic immune dysregulation detectable in peripheral blood and characterized by elevated cytokines, altered myeloid cell populations, and T-cell deficits.”
What the sources say
- Not checked yetcites [14] Porrata, 2019, Beware of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma, Leuk Lymphoma source
- Partly supportedcites [15] Porrata, 2010, Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio, Am J Hematol sourceExperimental — accuracy not yet measured
The discussion (p. 897) links a high blood neutrophil-to-lymphocyte ratio in patients with diffuse large B-cell lymphoma to inflammation and suggests that immune suppression could lower the absolute lymphocyte count. It does not establish elevated cytokines, altered myeloid-cell populations, or T-cell deficits in patients with active disease; the authors say the proposed mechanism needs prospective study. (LLM, conf=0.86)
- Partly supportedcites [16] Lin, 2011, Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma, Blood sourceExperimental — accuracy not yet measured
The Results and Discussion describe systemic immune suppression in peripheral blood, immunosuppressive monocytes, and reduced T-cell counts or function in patients with B-cell non-Hodgkin lymphoma. The Results report elevated VEGF, but not significantly elevated IL-6, IL-10, CCL-2, or TGF-β; the broad claim of elevated cytokines is therefore not supported. The paper also associates the monocyte phenotype with more aggressive disease rather than establishing the full pattern specifically for all patients with active disease. (LLM, conf=0.88)
- Partly supportedcites [17] Charbonneau, 2012, Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study, Cytokine sourceExperimental — accuracy not yet measured
Results §3.2 reports elevated serum levels of several cytokines in patients with follicular lymphoma or diffuse large B-cell lymphoma compared with controls. Methods §2.2 describes serum cytokine testing, not measurements of myeloid cell populations or T-cell deficits; the paper therefore does not support those parts of the claim. (LLM, conf=0.90)
- Not checked yetcites [18] Seymour, 1995, Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma, J Clin Oncol source
- Not checked yetcites [19] Preti, 1997, Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma, Ann Intern Med source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the pivotal ZUMA-1 trial, the degree of early axi-cel expansion in the peripheral blood associated with a DR.”
What the sources say
- Supportedcites [1] Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol source
The Results report that an ongoing response at 24 months was associated with higher peak CAR T-cell concentrations and greater area under the curve during the first 28 days after axi-cel infusion. The Methods (Procedures; page not available) specify that CAR T-cell concentrations were measured in blood. This supports the claim that greater early peripheral-blood expansion was associated with a durable response. (LLM, conf=0.94)
- Partly supportedcites [2] Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med sourceExperimental — accuracy not yet measured
The Results (Biomarkers; page not provided) report that early axi-cel expansion in peripheral blood was significantly associated with response. They do not establish an association specifically with durable response (DR); the Discussion describes the association as one with objective response. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When tumors express a gene signature (ISG.RS) consisting of genes coordinately activated by multiple types of IFN, a multigenic therapy resistance program is activated.”
What the sources say
- Could not verifycites [2] Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med sourceExperimental — accuracy not yet measured
Our copy of the ZUMA-1 trial (Neelapu et al. 2017, NEJM) addresses axi-cel efficacy, CAR T-cell expansion, cytokine-release syndrome and neurologic events; no passage mentions an interferon-stimulated gene signature (ISG.RS), interferon types, or a multigenic therapy-resistance program. Searched: 'ISG.RS interferon-stimulated gene signature therapy resistance', 'interferon gene expression tumor resistance program multigenic', and 'interferon signature gene expression tumor cell-of-origin resistance to therapy' — the top hits were the Results/Biomarkers and Discussion sections on serum cytokines (IL-6, -10, -15, -2Rα, GM-CSF, ferritin) and the reference list. The closest gene-expression content is the Methods (End Points and Assessments) noting cell-of-origin subtype by the NanoString Lymphoma Subtyping Test, which says nothing about interferon-driven resistance. Our copy neither supports nor contradicts the claim, and it credits the point to no other work. (LLM, conf=0.75)
- Partly supportedcites [24] Benci, 2016, Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade, Cell sourceExperimental — accuracy not yet measured
Our copy supports the core idea: tumor IFN signaling (type I and II, via STAT1) drives a 'multigenic resistance program' of TCIR ligands plus ISGs, which the authors define as IDILS (PDL1, TNFRSF14, LGALS9, MHCII, CD86, IFIT1, MX1) and which associates with clinical progression after anti-PD1 (RESULTS 'A Multigenic Resistance Program of TCIR Ligands and ISGs'; RESULTS 'High Expression of ISGs Can Associate with Clinical Progression After Anti-PD1'; DISCUSSION). However, the term 'ISG.RS' never appears in our copy (no exact-phrase hits; searches for 'ISG.RS' and 'coordinately activated' returned only semantic neighbours), and the ISG component is explicitly credited to another work — the 'ISGs that we previously described to be robustly expressed across human cancers (Weichselbaum et al., 2008)'. The claim's signature name and its framing that the signature itself activates resistance (rather than IFN/STAT1 signaling driving IDILS, with ISGs as correlative biomarkers) are therefore not stated by this paper. (LLM, conf=0.70)
- Partly supportedcites [54] Twyman-Saint Victor, 2015, Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer, Nature sourceExperimental — accuracy not yet measured
Our copy supports only part of this: the main text (Abstract/Results, Fig. 1g, Extended Data Fig. 2e) reports that transcriptomic profiling of resistant tumors (Res 499/177, Res 237) defined a multigenic RT + anti-CTLA4 'resistance gene signature' that includes PD-L1 together with interferon stimulated genes, and that PD-L1 was co-expressed with that signature in a metastatic melanoma patient cohort. However, the paper never names or defines a signature 'ISG.RS', never states that its genes are coordinately activated by multiple types of IFN (IFN-gamma is used only experimentally to induce PD-L1, and type I IFN is credited to separate LCMV works, refs 10-11), and it bounds the resistance program to resistance against radiation plus CTLA4 blockade rather than 'therapy resistance' generally. The claim's causal framing ('when tumors express ... a resistance program is activated') also exceeds the correlative gene-profiling evidence the paper presents, and the paper instead identifies elevated PD-L1 as the dominant resistance mechanism, with ISGs described only as genes that 'may promote immune suppression through PD-L1'. (LLM, conf=0.65)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These results suggest that a subset of LBCLs rely on tumor IFN signaling to mediate T-cell exhaustion and defend against antitumor immunity.23”
What the sources say
- Partly supportedcites [23] de Charette, 2018, Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy, Haematologica sourceExperimental — accuracy not yet measured
Our copy of de Charette et al. 2018 supports the surrounding elements of the claim but not its causal mechanism: the 'Defend' section (Inhibition / killing of immune cells) states that a subset of large B-cell lymphomas — DLBCL, more often ABC than GC (PD-L1 36% / 4% ; PD-L2 60% / 26%), PMBL (71%) and immune-privileged DLBCL with 9p24 alterations — inhibit T cells through PD-L1/PD-L2, LAG-3/MHC-II and HLA-G, and the Immunosuppressive microenvironment > Cytokines passage (p. n/a) describes an exhausted CTL phenotype (high PD-1 and TIM-3) in B-cell NHL. However, that exhaustion is attributed to tumor/microenvironment TGF-β (ref 123), not to tumor interferon signalling: five searches of our full-text copy (interferon, IFN, IFN-γ/type I IFN, JAK-STAT, tumor IFN signaling) returned no passage stating that tumor IFN signaling mediates T-cell exhaustion in LBCL — the only JAK reference is JAK2 within the 9p24 amplicon driving PD-L1/PD-L2 transcription. So the IFN-signaling element of the sentence is not supported by this source. (LLM, conf=0.68)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
78 more claims · 2 with their cited sources checked
Create a free account to see all 139 claims and to verify the 45 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 33
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The loss of antitumor efficacy has been attributed to CAR-T cell exhaustion in the tumor microenvironment17,18, or, to a lesser extent, immune evasion of malignant cells with loss of tumor surface antigen expression19.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results
“We compared TME gene expression according to NanoString in patients with a high ferritin level (>1000 ng/mL; n = 8) vs patients with lower ferritin levels (<1000 ng/mL; n = 28).”
§ Results
“We therefore used a NanoString limited gene expression panel enriched for genes of the TME on pretreatment biopsy specimens (n = 35).”
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationGenetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
Self-citationInterferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Self-citationChapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Cited by
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607
“Leukopenia‡ 55 (32) 50 (29) 43 (26) 37 (22)”
Self-citationRejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., et al. (2023) · Blood · doi:10.1182/blood.2023020578 · Cited by 358
Vitanza, N. A., Wilson, A. L., Huang, W., Seidel, K., Brown, C., Gustafson, J. A., Yokoyama, J. K., Johnson, A. J., Baxter, B. A., Koning, R. W., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0750 · Cited by 279
“DIPG tumors may also recruit immunoregulatory microglia and myeloid populations that limit CAR T-cell efficacy (54) as our MRM-MS data revealed heightened Figure 6.”
ResultDistinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., Gallagher, K. M. E., Katsis, K., Frigault, M. J., Southard, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01959-0 · Cited by 271
Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02234-6 · Cited by 255
Self-citationTumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Scholler, N., Perbost, R., Locke, F. L., Jain, M. D., Turcan, S., Danan, C., Chang, E. C., Neelapu, S. S., Miklos, D. B., Jacobson, C. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01916-x · Cited by 212
Self-citationRejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004475 · Cited by 202
“As recent studies have implicated pre- CAR-T inflammation as a negative prognostic marker, 17 18 we also investigated the prognostic value of the score.”
BackgroundSelf-citationWestin, J. R., Kersten, M. J., Salles, G., Abramson, J. S., Schuster, S. J., Locke, F. L., & Andreadis, C. (2021) · American Journal of Hematology · doi:10.1002/ajh.26301 · Cited by 199
Self-citationJacobson, C. A., Locke, F. L., Ma, L., Asubonteng, J., Hu, Z.-H., Siddiqi, T., Ahmed, S., Ghobadi, A., Miklos, D. B., Lin, Y., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.026 · Cited by 186
Self-citationNext-Generation CAR T-cell Therapies
Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N., & June, C. H. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1683 · Cited by 179
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 175
“Immune dysregulation in DLBCL treated with axi-cel showed that resistance to the CAR-T cell therapy centred on circulating mononuclear MDSCs and tumour IFN signalling, which led to insufficient axi-cel expansion as well as elevated expression of immune checkpoint ligands 192 .”
BackgroundImmunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
Jain, M. D., Smith, M., & Shah, N. N. (2023) · Blood · doi:10.1182/blood.2022017414 · Cited by 159
Self-citationChronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy
Hallek, M. J. (2025) · American Journal of Hematology · doi:10.1002/ajh.27546 · Cited by 209
Shouval, R., Tomas, A. A., Fein, J. A., Flynn, J. R., Markovits, E., Mayer, S., Afuye, A. O., Alperovich, A., Anagnostou, T., Besser, M. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02143 · Cited by 165
Rejeski, K., Hansen, D. K., Bansal, R., Sesques, P., Ailawadhi, S., Logue, J. M., Bräunlein, E., dos Santos, D. M. C., Freeman, C. L. L., Alsina, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01465-x · Cited by 168
“Systemic inflammatory markers have been linked to tumor interferon signaling and suppressive myeloid cells, which can blunt the CAR T-cell expansion necessary for efficient eradication of tumor cells [42, 43].”
BackgroundSelf-citationRecent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 146
“Increased PD-L1 expression by TAMs is associated with poorer outcomes in CART [92].”
BackgroundTreatment resistance in diffuse large B-cell lymphoma
He, M. Y., & Kridel, R. (2021) · Leukemia · doi:10.1038/s41375-021-01285-3 · Cited by 149
“Other potential mechanisms of CAR T-cell failure in DLBCL include elevation of T-cell inhibitory signaling, increased levels of tumor interferon signaling and circulating suppressive myeloid cells, and a high frequency of CD8 T-cell exhaustion signatures [103, 106, 107].”
BackgroundAdvancing CAR T cell therapy through the use of multidimensional omics data
Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 135
Locke, F. L., Filosto, S., Chou, J., Vardhanabhuti, S., Perbost, R., Dreger, P., Hill, B. T., Lee, C. J., Zinzani, P. L., Kröger, N. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02754-1 · Cited by 140
Self-citationAntigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
Lee, E. H. J., Murad, J. P., Christian, L., Gibson, J., Yamaguchi, Y., Cullen, C., Gumber, D., Park, A. K., Young, C. A., Monroy, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40115-1 · Cited by 121
Shadman, M. S., Pasquini, M. C., Ahn, K. W., Chen, Y., Turtle, C. J., Hematti, P., Cohen, J. B., Khimani, F., Ganguly, S., Merryman, R. W., et al. (2021) · Blood · doi:10.1182/blood.2021013289 · Cited by 131
Self-citationDhodapkar, K. M., Cohen, A. D., Kaushal, A., Garfall, A. L., Manalo, R. J., Carr, A. R., McCachren, S. S., Stadtmauer, E. A., Lacey, S. F., Melenhorst, J. J., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0018 · Cited by 115
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Hao, Z., Li, R., Wang, Y., Li, S., Hong, Z., & Han, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00333-5 · Cited by 104
“Interestingly, the same verdict has been mentioned in a study of refractory/relapsed large B lymphoma treated with CAR-T therapy (Axicabtagene ciloleucel) where high blood levels of M-MDSC, IL-6, and ferritin were associated with a lack of durable response to treatment [157].”
ResultJain, M. D., Ziccheddu, B., Coughlin, C. A., Faramand, R., Griswold, A. J., Reid, K. M., Menges, M., Zhang, Y., Cen, L., Wang, X., et al. (2022) · Blood · doi:10.1182/blood.2021015008 · Cited by 91
Self-citationJiang, C., Hao, D., Jain, P., Li, Y., Cai, Q., Yao, Y., Nie, L., Liu, Y., Jin, J., Wang, W., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01655-0 · Cited by 90
Rejeski, K., Jain, M. D., & Smith, E. L. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.04.007 · Cited by 93
Self-citationBiomarkers for prediction of CAR T therapy outcomes: current and future perspectives
Sršen, L., Janžič, L., Ihan, A., & Kopitar, A. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378944 · Cited by 80
“These characteristics may in fl uence the course and outcome of CAR T cell therapy (19, 27, 29, 37, 84, 109, 110).”
BackgroundInfluentialMonocytes in Tumorigenesis and Tumor Immunotherapy
Chen, X., Li, Y., Xia, H., & Chen, Y. H. (2023) · Cells · doi:10.3390/cells12131673 · Cited by 77
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
Raj, S. S., Fei, T., Fried, S., Ip, A., Fein, J. A., Leslie, L. A., Tomás, A. A., Leithner, D., Peled, J. U., Corona, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03532-x · Cited by 76
“Covariance between uncommonly assessed cytokines directly related to immune activation (that is, IL-6 and IL-10) 25,26 and commonly accessible measures such as albumin, Hgb, and LDH informed cluster assignment and outcome prediction.”
InfluentialLi, W., Zhang, B., Cao, W., Zhang, W., Li, T., Liu, L., Xu, L., Gao, F., Wang, Y., Wang, F., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00402-5 · Cited by 70
“High interferon signaling could induce high expressions of PD-L1 and MHC-II in tumor cells, which bind to PD-1 and LAG3 on the surface of T cells, respectively, and results in reduced CAR-T cell expansion and increased exhaustion [73].”
BackgroundRejeski, K., Perez, A. P., Iacoboni, G., Blumenberg, V., Bücklein, V., Völkl, S., Penack, O., Albanyan, O., Stock, S., Müller, F., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3919 · Cited by 69
Self-citationRiding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Hughes, A. D., Teachey, D. T., & Diorio, C. J. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01013-w · Cited by 75
Zhou, X., Wang, Y., Dou, Z., Delfanti, G., Tsahouridis, O., Pellegry, C. M., Zingarelli, M., Atassi, G., Woodcock, M. G., Casorati, G., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00830-0 · Cited by 64
“CAR-T cell exhaustion caused by chronic antigen stimulation in patients with bulky disease and tumor-intrinsic immunosuppressive mechanisms are both considered key factors contributing to CAR-T cell failure in patients with lymphoid malignancies 46–48 .”
Hirayama, A. V. V., Kimble, E. L., Wright, J. H., Fiorenza, S., Gauthier, J., Voutsinas, J. M., Wu, Q. V., Yeung, C. C. S., Gazeau, N., Pender, B. S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011287 · Cited by 62
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy: A Review
Ventin, M., Cattaneo, G., Maggs, L., Arya, S., Wang, X., & Ferrone, C. R. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4504 · Cited by 69
Self-citationRejeski, K., dos Santos, D. M. C., Parker, N. H., Bücklein, V., Winkelmann, M., Jhaveri, K. S., Liu, L., Trinkner, P., Günther, S., Karschnia, P., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0487 · Cited by 62
Self-citationRejeski, K., Wang, Y., Albanyan, O., Munoz, J. L., Sesques, P., Iacoboni, G., López‐Corral, L., Ries, I., Bücklein, V., Mohty, R., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27056 · Cited by 68
“53 Similarly, an increase of both myeloid cells and exhausted T-cell populations was observed in MCL patients relapsing after CAR T in a recent study by Jiang and colleagues.”
Self-citationMaura, F., Boyle, E. M., Coffey, D. G., Maclachlan, K. H., Gagler, D. C., Diamond, B. T., Ghamlouch, H., Blaney, P., Ziccheddu, B., Cirrincione, A. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00657-1 · Cited by 66
“These two pathways have also been linked with better clinical outcomes in other tumors after immunotherapy 33,42 , as well as with treatment response to anti-BCMA CAR-T therapy in MM 18 .”
Filosto, S., Vardhanabhuti, S., Canales, M. Á., Poiré, X., Lekakis, L. J., de Vos, S., Portell, C. A., Wang, Z., To, C., Schupp, M., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0112 · Cited by 64
“The opposite was observed in ZUMA-7, the reason for which is unclear but may include different products/constructs”
BackgroundBiomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
Gyurdieva, A. V., Zajic, S. C., Chang, Y.-F., Houseman, E. A., Zhong, S., Kim, J., Nathenson, M. J., Faitg, T. H., Woessner, M. A., Turner, D. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32491-x · Cited by 58
CAR T‐cell therapy in large B cell lymphoma
Boardman, A. P., & Salles, G. A. (2023) · Hematological Oncology · doi:10.1002/hon.3153 · Cited by 66
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
Bock, T., Colonne, C. K., Fiorenza, S., & Turtle, C. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-00992-5 · Cited by 60
Recognizing, defining, and managing CAR-T hematologic toxicities
Rejeski, K., Subklewe, M. S., & Locke, F. L. (2023) · Hematology · doi:10.1182/hematology.2023000472 · Cited by 59
Self-citationCAR T cell therapies for diffuse midline glioma
Thomas, B. C., Staudt, D. E., Douglas, A. M., Monje, M., Vitanza, N. A., & Dun, M. D. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.007 · Cited by 53
Yan, Z., Dong, Y., Qiao, N., Zhang, Y., Wu, W., Zhu, Y., Wang, L., Cheng, S., Xu, P.-P., Zhou, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49495-4 · Cited by 59
dos Santos, D. M. C., Rejeski, K., Winkelmann, M., Liu, L., Trinkner, P., Günther, S., Bücklein, V., Blumenberg, V., Schmidt, C., Kunz, W. G., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280189 · Cited by 52
“Basic data Age in years, median (range) Female patients, N (%) 61 (19-82) 23 (35.”
BackgroundBaseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Faramand, R. G., Lee, S. B., Jain, M. D., Cao, B., Wang, X., Rejeski, K., Subklewe, M. S., Fahrmann, J. F., Saini, N. Y., Hanash, S., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0056 · Cited by 52
“We validated findings in an independent, deidentified data set of 139 patients treated per standard of care with either axi-cel ( n = 49) or tisa-cel ( n = 90) for R/R DLBCL as previously reported across European centers (15, 23).”
BackgroundInfluentialSelf-citationReducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release
Zhang, A., Sun, Y., Du, J., Dong, Y., Pang, H., Ma, L., Si, S., Zhang, Z., He, M., Yue, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724211 · Cited by 55
“IFN signaling is associated with the expression of multiple checkpoint ligands and inferior response to CAR-T therapy (46).”
BackgroundRelapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches
Gu, T., Zhu, M., Huang, H., & Hu, Y. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200256 · Cited by 55
“Tumor interferon (IFN) signaling is cor‐ related with macrophage content in the TME while exerting suppression on CAR-T cells by up-regulating programmed cell death-ligand 1 (PD-L1) and MHC-II on the tumor cell surface (Jain et al., 2021).”
BackgroundLarge B cell lymphoma microenvironment archetype profiles
Li, X., Singhal, K., Deng, Q., Chihara, D., Russler‐Germain, D. A., Harkins, R. A., Henderson, J. M., Arita, K., Kizhakeyil, A., Sun, R., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.002 · Cited by 60
Major, A., Yu, J., Shukla, N., Che, Y., Karrison, T. G., Treitman, R., Kamdar, M. K., Haverkos, B. M., Godfrey, J. K., Babcook, M. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010016 · Cited by 48
“0) Median time to recurrence after CAR-T, d (range) 84 (4-624)”
BackgroundLeithner, D., Flynn, J. R., Devlin, S. M., Mauguen, A., Fei, T., Zeng, S., Zheng, J., Imber, B. S., Hubbeling, H., Mayerhoefer, M. E., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01540-x · Cited by 47
Cox, M. J., Roman, C. M., Tapper, E. E., Siegler, E. L., Chappell, D. B., Durrant, C., Ahmed, O., Sinha, S., Mwangi, R., Scott, N. E., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01572-7 · Cited by 44
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
Blumenberg, V., Busch, G., Baumann, S., Jitschin, R., Iacoboni, G., Gallur, L., Iraola‐Truchuelo, J., Hoster, E., Winkelmann, M., Hellwig, K., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010364 · Cited by 42
Noncanonical and mortality-defining toxicities of CAR T cell therapy
Rejeski, K., Hill, J. A., Dahiya, S., & Jain, M. D. (2025) · Nature Medicine · doi:10.1038/s41591-025-03813-5 · Cited by 46
“In addition, large tumors drive systemic inflammation, which ‘primes’ myeloid and other immune cells to amplify the cytokine release initiated by the CAR T cells, further exacerbating toxicity 47–49 .”
Self-citationLocke, F. L., Neelapu, S. S., Bartlett, N. L., Lekakis, L. J., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.08.018 · Cited by 50
Self-citationRejeski, K., Blumenberg, V., Iacoboni, G., López‐Corral, L., Kharboutli, S., Hernani, R., Petrera, A., Müller, N., Hildebrand, F., Frölich, L., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000858 · Cited by 43
Caballero, A. C., Escribà-García, L., Álvarez‐Fernández, C., & Briones, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904497 · Cited by 41
“If this study represents a measure of the product quality or specific antitumor, T-cell subsets remain an unanswered question so far, as well as the reproducibility of these data in a larger dataset of patients (33).”
BackgroundResultRole of the tumor microenvironment in CLL pathogenesis
Stein, A. F. V., Hallek, M. J., & Nguyen, P. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.12.004 · Cited by 46
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations
Perna, F., Parekh, S. S., Diorio, C. J., Smith, M. M., Subklewe, M., Mehta, R. P., Locke, F. L., & Shah, N. N. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013044 · Cited by 44
“47 However, the impact of emapalumab on the long-term ef fi cacy of CAR T cells and infection risk in this patient population has not been systematically examined.”
BackgroundSelf-citationCanelo‐Vilaseca, M., Sabbah, M., Blasi, R. D., Cristinelli, C., Sureda, A. M., Caillat‐Zucman, S., & Thiéblemont, C. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02539-9 · Cited by 43
“A less positive effect of LD, although controversial, is that they could increase the levels of myeloid-derived suppressor cells (MDSCs), liable to impair CAR-T ef fi cacy, through mobilization of hematopoietic progenitor cells from the bone marrow [16, 20, 43, 48, 49].”
Wada, F., Jo, T., Arai, Y., Kitawaki, T., Mizumoto, C., Kanda, J., Nishikori, M., Yamashita, K., Nagao, M., & Takaori‐Kondo, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-23589-9 · Cited by 36
Bücklein, V., Perez, A. P., Rejeski, K., Iacoboni, G., Jurinović, V., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000907 · Cited by 38
“26 This in turn negatively influences CAR T-cell expansion and confers resistance of the underlying lymphoma to CD19 CAR-T.”
BackgroundSelf-citationWright, K., Weirather, J. L., Jiang, S., Kao, K. Z., Sigal, Y. M., Giobbie‐Hurder, A., Shipp, M. A., & Rodig, S. J. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009813 · Cited by 43
“Indeed, it was recently reported that a subset of patients with DLBCLs and high T-cell content respond to PD-1 blockade, unlike the vast majority of patients with DLBCL,(31) and that a subset of patients with DLBCLs and a transcriptionally-defined inflamed microenvironment respond poorly to chimeric antigen receptor T…”
BackgroundHarnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 40
Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies
Bhardwaj, V., & Ansell, S. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1129343 · Cited by 38
Wood, A. C., Perez, A. P., Arciola, B., Patel, K., Johnson, G., DiMaggio, E. C., Bachmeier, C. A., Reid, K. M., Corallo, S. A., Vargas, M. H., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.09.009 · Cited by 39
Self-citationCSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
Stahl, D. J., Gödel, P., Balke‐Want, H., Gholamipoorfard, R., Segbers, P., Tetenborg, L., Koker, M., Dörr, J., Gregor, L., Bachurski, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.013 · Cited by 44
Ziccheddu, B., Giannotta, C., D’Agostino, M., Bertuglia, G., Saraci, E., Oliva, S., Genuardi, E., Papadimitriou, M., Diamond, B. T., Corradini, P., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01096-6 · Cited by 36
Ma, C., Wang, H., Liu, L., Chen, R., Mukherjee, N., Tong, J., Kazmi, S., Fang, X., Witkowski, M. T., Aifantis, I., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01428-2 · Cited by 40
“Our understanding of the dynamic changes in the leukaemia bone marrow microenvironment during CAR T cell therapy responses such as resistance or effective killing is limited, which may prevent unleash-ing its full therapeutic potential 43,44 .”
Ramos, A., Koch, C. E., Liu-Lupo, Y., Hellinger, R. D., Kyung, T., Abbott, K. L., Fröse, J., Goulet, D. R., Gordon, K. S., Eidell, K. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43790-2 · Cited by 37
Ventin, M., Cattaneo, G., Arya, S., Jia, J., Gelmi, M. C., Sun, Y., Maggs, L., Ksander, B. R., Verdijk, R. M., Boland, G. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0071 · Cited by 36
Self-citationQuantitative PET-based biomarkers in lymphoma: getting ready for primetime
Alderuccio, J. P., Kuker, R. A., Yang, F., & Moskowitz, C. H. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00799-2 · Cited by 35
The effects of electron scattering and wind clumping for early emission line stars
Hillier, D. J. (1991) · Cited by 30
Brouwer‐Visser, J., Fiaschi, N., Deering, R. P., Cygan, K. J., Scott, D., Jeong, S., Boucher, L., Gupta, N., Gupta, S., Adler, C., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008338 · Cited by 34
New insights into CAR T cell-mediated killing of tumor cells
Espie, D., & Donnadieu, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016208 · Cited by 31
“Conversely, IFNg signaling in B-cell lymphoma has been associated with CAR T cell failure (26).”
BackgroundMechanistic insights into resistance mechanisms to T cell engagers
Cao, L., Leclercq-Cohen, G., Klein, C., Sorrentino, A., & Bacac, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583044 · Cited by 42
Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment
Frosch, J., Leontari, I., & Anderson, J. (2021) · Cancers · doi:10.3390/cancers13071743 · Cited by 29
CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights
Ali, A., Goy, A. H., & Dunleavy, K. M. (2022) · Blood · doi:10.1182/blood.2022016226 · Cited by 28
Fan, R., Beule, N. D., Maes, A., Bruyne, E. D., Menu, E., Vanderkerken, K., Maes, K., Breckpot, K., & Veirman, K. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016059 · Cited by 30
“More recently, a study in B-NHL patients including CLL, DLBCL, marginal zone lymphoma (MZL), high‐grade B‐cell lymphoma (HGBL), mantle‐cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) and follicular lymphoma (FL) patients was carried out to investigate the impact of MDSC number and subsets (CD14+CD…”
BackgroundInfluentialWinkelmann, M., Blumenberg, V., Rejeski, K., Bücklein, V., Ruzicka, M., Unterrainer, M., Schmidt, C., Dekorsy, F. J., Bartenstein, P., Ricke, J., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06075-2 · Cited by 27
Tumor microenvironment and CAR‐T cell immunotherapy in B‐cell lymphoma
Cai, F., Zhang, J., Gao, H. Y., & Shen, H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14103 · Cited by 32
Li, X., Li, W., Xu, L., & Song, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002818 · Cited by 27
Maurer, K., Grabski, I. N., Houot, R., Gohil, S. H., Miura, S., Redd, R. A., Lyu, H., Lu, W. S., Arihara, Y., Budka, J. A., et al. (2024) · Blood · doi:10.1182/blood.2024024381 · Cited by 33
Arunachalam, A. K., Grégoire, C., de Oliveira, B. C., & Melenhorst, J. J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101241 · Cited by 30
Razzo, B. M., Midha, S., Portuguese, A. J., Grajales-Cruz, A. F., Corraes, A. D. M. S., Costello, P., Liu, Y., Sperling, A. S., Nadeem, O., Dima, D., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0354 · Cited by 25
Lau, E. K., Kwong, G., Fowler, T. W., Sun, B.-C., Donohoue, P. D., Davis, R. T., Bryan, M. B., McCawley, S., Clarke, S., Williams, C., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.03.011 · Cited by 26
Carniti, C., Caldarelli, N., Agnelli, L., Torelli, T., Ljevar, S., Jonnalagadda, S., Zanirato, G., Fardella, E., Stella, F., Lorenzini, D., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012563 · Cited by 30
“36 Of interest, in contrast to other studies that have recently identi fi ed a link between circulating MDSCs and CAR T cells in patients with LBCL, 37,38 in our study, quantities of Mo-MDSCs assessed by MFC in leukaphe-resis products, are neither associated with the signature nor with the outcome.”
ResultCAR-T failure: beyond antigen loss and T cells
Strati, P., & Neelapu, S. S. (2021) · Blood · doi:10.1182/blood.2020010462 · Cited by 25
The contribution of the monocyte-macrophage lineage to immunotherapy outcomes
Adams, R. C., MacDonald, K. P. A., & Hill, G. R. (2024) · Blood · doi:10.1182/blood.2024025680 · Cited by 28
CAR-iNKT cells: redefining the frontiers of cellular immunotherapy
Niedzielska, M., Chalmers, A., Popis, M. C., Altman-Sharoni, E., Addis, S., Beulen, R., Rudqvist, N.-P., Chantzoura, E., Purbhoo, M. A., Chand, D. S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1625426 · Cited by 28
Sarcoma IL-12 overexpression facilitates NK cell immunomodulation
Rademacher, M. J., Cruz, A., Faber, M. L., Oldham, R. A. A., Wang, D., Medin, J. A., & Schloemer, N. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87700-2 · Cited by 23
Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response
Liu, C., Qi, T., Milner, J. J., Lu, Y., & Cao, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748768 · Cited by 26
Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
Samur, M., Samur, A. A., Corre, J., Lannes, R., Shah, P. S., Anderson, K. C., Avet‐Loiseau, H., & Munshi, N. C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010025 · Cited by 23
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
Bourbon, E., Sesques, P., Gossez, M., Tordo, J., Ferrant, E., Safar, V., Wallet, F., Aussedat, G., Maarek, A., Bouafia, F., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2021006563 · Cited by 24
“In a smaller cohort of LBCL treated with anti-CD19 CAR T cells, they demonstrated an inflammation-mediated resistance to CAR T cells linked to IFN signaling and M-MDSCs.(14) Similar findings came from Jaeger et al and Michael, who”
BackgroundMethodResultInfluentialJacobs, M. T., Jain, M. D., Gao, F., Nastoupil, L. J., Spiegel, J. Y., Lin, Y., Dahiya, S., Lunning, M. A., Lekakis, L. J., Reagan, P. M., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.05.004 · Cited by 22
Self-citationStrati, P., Jallouk, A. P., Sun, R., Choi, J., Das, K., Cherng, H.-J. J., Ahmed, S., Lee, H. J., Iyer, S. P., Nair, R. K., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01704-z · Cited by 20
“Furthermore, high levels of circulating monocytic MDSCs have been associated with lower peak CAR T-cell expansion [32, 33].”
BackgroundCAR T cell therapy: looking back and looking forward
Davila, M. L., & Brentjens, R. J. (2022) · Nature Cancer · doi:10.1038/s43018-022-00484-w · Cited by 19
Self-citationChallenges and optimal strategies of CAR T therapy for hematological malignancies
Zhang, Y., Yang, X., Dang, X., Zhu, Z., Qian, W., Liang, A., & Han, W. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002476 · Cited by 20
Metadata
- Authors
- Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., Cao, B., Chavez, J. C., Shah, B., Lazaryan, A., Nishihori, T., Hussaini, M., Gonzalez, R. J., Mullinax, J. E., Rodriguez, P. C., Conejo-Garcia, J. R., Anasetti, C., Davila, M. L., & Locke, F. L.
- Affiliations
- Department of Blood and Marrow Transplant and Cellular Immunotherapy,
- Department of Clinical Science,
- Department of Bioinformatics and Biostatistics,
- Department of Malignant Hematology,
- Department of Pathology,
- Department of Sarcoma, and
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL
- University of South Florida (US)
- Corresponding author
- Jain, Michael D.
- Zhao, Hua
- ORCID
- Jain, Michael D.
- Zhao, Hua
- Wang, Xuefeng
- Atkins, Reginald
- Menges, Meghan
- Reid, Kayla
- Faramand, Rawan
- Bachmeier, Christina
- Dean, Erin A.
- Cao, Biwei
- Shah, Bijal
- Lazaryan, Aleksandr
- Nishihori, Taiga
- Gonzalez, Ricardo J.
- Mullinax, John E.
- Rodriguez, Paulo C.
- Conejo-Garcia, Jose R.
- Anasetti, Claudio
- Davila, Marco L.
- Locke, Frederick L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-05-13
- Volume
- 137
- Issue
- 19
- Pages
- 2621-2633
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC8120145
- OpenAlex
- W3123125599
- Semantic Scholar
- be4a1f2554f696107aa788eb12aaa850563c1cf0
- Cited by
- 297
- References
- 60
- Citations by year
- 2026: 40 · 2025: 63 · 2024: 54 · 2023: 72 · 2022: 43 · 2021: 23
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA184185, K23CA201594, P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- large B-cell lymphoma, axicabtagene ciloleucel, CAR T-cell therapy, treatment failure, interferon signaling, myeloid-derived suppressor cells, immune checkpoint ligands, PD-L1, interleukin-6, ferritin, immune dysregulation, CAR-T cell expansion, tumor burden, relapsed/refractory lymphoma
- MeSH terms
- Myeloid-Derived Suppressor Cells, Receptors, Chimeric Antigen, Adult, Aged, Biological Products, Female, Ferritins, Humans, Interferons, Male, Middle Aged, RNA, Neoplasm, Cytokines, Immunotherapy, Adoptive, Lymphoma, B-Cell, Treatment Failure, Tumor Escape, Tumor Burden, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.